Tanja Fehm, Natalia Krawczyk, Erich-Franz Solomayer, Graziella Becker-Pergola, Silke Dürr-Störzer, Hans Neubauer, Harald Seeger, Annette Staebler, Diethelm Wallwiener, and Sven Becker
Abstract:
Introduction
Isolated disseminated tumour cells (DTC) are regarded as surrogate markers for minimal residual disease in breast cancer. Characterisation of these cells could help understand the known limitations of adjuvant therapy. Of particular interest is their oestrogen-receptor (ER) status because endocrine adjuvant therapy remains a cornerstone of breast cancer treatment.